These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15623615)

  • 41. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
    Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
    Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation.
    Robinson BW; Behling KC; Gupta M; Zhang AY; Moore JS; Bantly AD; Willman CL; Carroll AJ; Adamson PC; Barrett JS; Felix CA
    Br J Haematol; 2008 Jun; 141(6):827-39. PubMed ID: 18422996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
    Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
    Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
    Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
    Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
    Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
    J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine.
    Xu Z; Friess H; Solioz M; Aebi S; Korc M; Kleeff J; Büchler MW
    Int J Cancer; 2001 Oct; 94(2):268-74. PubMed ID: 11668508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
    Gallerne C; Prola A; Lemaire C
    Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of bcl-2 antisense oligonucleotides on multidrug resistance of cultured uveal melanoma cells].
    Guo LJ; Wu ZY; Zhang S; Zheng JL; Zheng HL
    Zhonghua Yan Ke Za Zhi; 2003 Feb; 39(2):73-6. PubMed ID: 12783683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
    Lacy J; Loomis R; Grill S; Srimatkandada P; Carbone R; Cheng YC
    Int J Cancer; 2006 Jul; 119(2):309-16. PubMed ID: 16477627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.
    Kelly JD; Dai J; Eschwege P; Goldberg JS; Duggan BP; Williamson KE; Bander NH; Nanus DM
    Br J Cancer; 2004 Jul; 91(1):164-70. PubMed ID: 15188008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
    Moulder SL; Symmans WF; Booser DJ; Madden TL; Lipsanen C; Yuan L; Brewster AM; Cristofanilli M; Hunt KK; Buchholz TA; Zwiebel J; Valero V; Hortobagyi GN; Esteva FJ
    Clin Cancer Res; 2008 Dec; 14(23):7909-16. PubMed ID: 19047121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
    Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide.
    Huang Z; Lei X; Zhong M; Zhu B; Tang S; Liao D
    Acta Biochim Biophys Sin (Shanghai); 2007 Nov; 39(11):835-43. PubMed ID: 17989874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.